Evaluation of Infections in Hospitalised Pregnant Women
PDF
Cite
Share
Request
RESEARCH ARTICLE
P: 23-23
January 2018

Evaluation of Infections in Hospitalised Pregnant Women

Mediterr J Infect Microb Antimicrob 2018;7(1):23-23
1. University of Health Sciences, Ankara Numune Health Practice and Research Center, Clinic of Infectious Diseases and Clinical Microbiology, Ankara, Turkey
2. University of Health Sciences, Ankara Numune Health Practice and Research Center, Clinic of Obstetrics and Gynecology, Ankara, Turkey
No information available.
No information available
PDF
Cite
Share
Request

Summary

Introduction: Hormonal and immunological changes in pregnancy may lead to an increase in infectious diseases caused by some pathogens. In this study, we aimed to determine the types of infections and treatment approaches in pregnant women who were hospitalized due to infectious diseases.

Materials and Methods: This retrospective study included 87 pregnant women who were hospitalized in the Infectious Diseases and Clinical Microbiology and Obstetrics and Gynecology Clinics of the University of Health Sciences, Ankara Numune Training and Research Hospital between January 2011 and December 2016.

Results: The median age of the 87 pregnant women was 23 years, and 40 of them were in the second trimester. Analysis of infection diagnoses showed that urinary tract infection (UTI) was the most common infection (59 patients, 67.8%). Most of the patients with UTI developed pyelonephritis (42 patients, 71.1%). Twenty-five patients" urine culture yielded a pathogen in urine culture while Escherichia coli was the most common isolate. Seven of the isolated strains were extended-spectrum beta-lactamase (ESBL) producers. Ceftriaxone was started in 35 of the patients with pyelonephritis. Treatment duration was 5-17 days (mean 11 days). Other infections were acute gastroenteritis, pneumonia, influenza, varicella, measles, tularemia, brucellosis, Crimean-Congo hemorrhagic fever, adult-onset Still"s disease, acute viral hepatitis A and B coinfection, and perianal abscess.

Conclusion: UTI is the most common infection in pregnant women. E. coli is the most commonly isolated microorganism and the rate of ESBLpositive isolates is increasing. Pyelonephritis is more common than other UTI and requires hospitalization.

Keywords:
Pregnancy, urinary system infection, brucellosis, CCHF, ESBL

Introduction

Urinary tract infections (UTIs) are the most common infections during pregnancy and may affect 20% of women of childbearing age[4, 5]. The most important risk associated with asymptomatic bacteriuria (ASB) during pregnancy is the development of pyelonephritis. It is known that pyelonephritis can occur in 20- 30% of pregnant women with untreated ASB[6]. Therefore, early diagnosis and treatment of ASB during pregnancy is important.

Pregnant women, children under 2 years of age, adults over 65 years of age, and individuals with chronic illness constitute a high-risk group for seasonal influenza[7]. Pressure exerted by the fetus reduces the expansion capacity of the lungs and limits their ability to expel secretions, resulting in a higher risk of pneumonia for pregnant women[8].

This study was conducted to determine the types of infections detected and the treatment approaches used in pregnant patients admitted to our hospital due to infection. In this way, we aimed to contribute to the epidemiologic data.

Methods

Ethical approval was obtained from the Ankara Numune Training and Research Hospital Ethics Committee before initiating the study (date and number of approval: 05.07.2017, 17-1466).

Results

Table 1: Distribution of patients according to infection diagnosis

The majority of patients with UTI had pyelonephritis (71.1%, n=42). Of the patients diagnosed with pyelonephritis, all had dysuria and 95.2% (n=40) had costovertebral angle tenderness and fever. In addition, 26 patients had hydronephrosis and five patients had nephrolithiasis. Mean white blood cell (WBC) count was 16,290/mm3. Urine culture yielded a pathogen in 25 (59.5%) of these patients. Escherichia coli (E. coli) was most frequently isolated causative agent (Table 2). Seven of the causative agents were extended-spectrum beta-lactamase (ESBL)-positive (2 Klebsiella pneumonia, 4 E. coli, 1 Pseudomonas spp.). Thirty-five of the patients diagnosed with pyelonephritis were started on ceftriaxone, and treatment was changed in 8 of these patients based on their antibiogram results (2 received ertapenem, 4 received meropenem, and 2 received sulbactam/ampicillin). Of the remaining 7 patients, 3 received meropenem, 3 received ertapenem, and 1 received sulbactam/ampicillin. Treatment lasted for 5-17 days (mean 11 days).

Table 2: Causative agents isolated in urine culture

Urine cultures yielded a pathogen in 9 of the 15 patients diagnosed with cystitis. E. coli was the most common causative agent isolated in culture (n=7) (Table 3). One E. coli strain was ESBL-positive. Patients diagnosed with cystitis had a mean WBC count of 12,620/mm3 and a mean C-reactive protein level of 33.5 mg/L. The patients were treated with ceftriaxone (n=10), ertapenem (n=3), sulbactam-ampicillin (n=1), or cefazolin (n=1) for a duration of 7-10 days. The patient diagnosed with urosepsis had E. coli growth in blood and urine cultures and was treated with ceftriaxone for 14 days.

Table 3: Number of patients diagnosed with urinary tract infection according to trimester of pregnancy

Evaluation of the relationship between UTI diagnoses and gestational week revealed that most of the patients were admitted during the second trimester (Table 3).

Of the 13 patients with gastroenteritis, five patients with fever and findings of fecal leukocytosis were treated with antibiotics (ceftriaxone for three, metronidazole for two), while the others were provided hydration support only. No pathogenic bacterial growth was observed in fecal cultures. One patient went into labor at 36 weeks of gestation.

Of the patients with respiratory symptoms, four were diagnosed with pneumonia and treated with sulbactam-ampicillin, while three were found to have influenza A and were treated with oseltamivir (five days). Two of the patients with influenza A were in the first trimester and the other was in the second trimester, and none developed complications.

A woman at 8 weeks of gestation was diagnosed with Crimean- Congo hemorrhagic fever (CCHF) as a result of a tick bite and developed miscarriage following vaginal bleeding and subchorionic hematoma. She was discharged in good condition after 10 days.

A woman at 13 weeks of gestation who was admitted to the obstetrics unit due to thyrotoxicosis, pancytopenia, and elevated liver function test (LFT) results underwent total thyroidectomy and was treated with ceftriaxone and rifampicin for six weeks due to Brucella spp. growth in two postoperative blood cultures, and she fully recovered on follow up.

A woman at 29 weeks of gestation was diagnosed with chickenpox and another woman at 24 weeks of gestation was diagnosed with measles. They were both followed with symptomatic treatment and recovered with no complications. A patient at six weeks of gestation with elevated LFT results tested positive for anti-HBc IgM (+) and anti-HAV IgM (+) and was monitored for 6 days with a diagnosis of acute hepatitis A and B coinfection. She was discharged while follow-up LFT results showed regression.

A 22-week pregnant woman with fever and elevated LFT results (alanine aminotransferase: 204 u/l, aspartate aminotransferase: 276 u/l, lactate dehydrogenase: 1675 u/l) was hospitalized with complaints of fever, joint pain, myalgia, and maculopapular rash for ten days. During follow-up, her WBC count decreased to 3600/mm3 and platelet count decreased to 49,000/mm3, after which LFT and hemogram values improved. Brucella tube agglutination, Rose Bengal, viral hepatitis markers, and TORCH screen (toxoplasmosis, rubella cytomegalovirus, herpes simplex, and HIV) were negative. Parvovirus IgM and PCR were negative, measles IgG was positive, autoimmune (antinuclear antibody, rheumatoid factor, antimitochondrial antibodies) markers were negative, and ferritin level was >2000 ng/ml, and no focus of infection was detected. The patient was diagnosed with adult-onset Still"s disease, started on methylprednisolone, and followed in the rheumatology clinic.

Microagglutination assay for tularemia performed on a woman at 27 weeks of gestation with swelling on the left side of her neck and a sore throat yielded a result of 1/320, and the patient was hospitalized with a diagnosis of tularemia. Due to the toxic fetal effects of the medication recommended to treatment tularemia, the patient refused treatment and was discharged by her own will with recommendation to return for follow-up. However, we learned that the patient did not attend follow-up appointments after discharge.

A perianal abscess was detected in a woman at ten weeks of gestation. She presented with complaints of nausea, vomiting, and perianal pain, and was treated with ertapenem for 14 days.

Discussion

The causative agents of UTIs in pregnant women and their virulence are similar to those in non-pregnant women[17]. The most common causative agent is E. coli. In one study, E. coli was identified as the most common causative agent in patients with pyelonephritis, at a rate of 70%[18]. E. coli was also found to be the most common causative agent in our study. Increasing antibiotic resistance is an important problem today. Even in uncomplicated UTIs, the prevalence of ESBL-producing strains is increasing[19, 20]. In a study conducted in India, it was reported that ESBL-producing uropathogens were a problem for pregnant females[21]. In our study, ESBL positivity was detected in 15.2% (9/59) of patients diagnosed with UTI.

Crimean-Congo hemorrhagic fever is an acute viral infection that can be fatal and has no definitive treatment. Data on CCHF during pregnancy are limited. However, mortality is reported to be higher in pregnant women than in the general population[22]. A review of 41 pregnant women diagnosed with CCHF reported 34% maternal mortality and 58.5% fetal/neonatal mortality[23]. There is no specific antiviral therapy for CCHF and the effectiveness of ribavirin therapy is still being discussed[24]. Our patient had a miscarriage but was discharged in good condition.

Although complications such as miscarriage and intrauterine death are seen in animals due to tularemia, data on infection in human pregnancy are very limited[25]. Tularemia during pregnancy may lead to prematurity or fetal loss. However, healthy newborns who were not adversely affected by maternal tularemia have also been reported[26-30]. There is no consensus regarding the treatment of tularemia during pregnancy. In one publication, two of three pregnant tularemia patients were followed without treatment while one was treated with gentamicin, and it was reported that all three patients reached full term with no maternal or fetal complications[26].

Pregnant women are at a 4-5 times higher risk of influenza A infection compared to healthy non-pregnant women. In addition, the disease course varies between stage of pregnancy, and women at term are hospitalized 5 times more than women earlier in pregnancy or postpartum[31]. Early treatment with antiviral therapy is recommended for pregnant women with suspected influenza. Oseltamivir is a pregnancy category C drug. However, due to the serious complications of influenza, the benefits of antiviral therapy outweigh the potential risks of antiviral drug use in pregnant women[32]. In the present study, all three patients with influenza A were in the first or second trimesters, all received antiviral therapy, and no complications were observed.

Conclusion

Ethics
Ethics Committee Approval: Ethical approval was obtained from the Ankara Numune Training and Research Hospital Ethics Committee before initiating the study (date and number of approval: 05.07.2017, 17-1466).

Informed Consent: Retrospective study.
Peer-review: Externally and internally peer-reviewed.

Authorship Contributions
Concept: H.B., C.R.A., E.A., Design: H.B., E.A., B.Ö., Data Collection or Processing: B.Ö., S.K., Analysis or Interpretation: B.Ö., Literature Search: B.Ö., S.K., E.A., Writing: B.Ö.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1
Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28:521-74.
2
Robinson DP, Klein SL. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Horm Behav. 2012; 62:263-71.
3
Mor G, Cardenas I. The immune system in pregnancy: a unique complexity. Am J Reprod Immunol. 2010;63:425-33.
4
Parveen K, Momen A, Begum AA, Begum M. Prevalence of urinary tract infection during pregnancy. J Dhaka Natl Med Coll Hos. 2012;17:8-12.
5
Lawani EU, Alade T, Oyelaran D. Urinary tract infection amongst pregnant women in Amassoma, Southern Nigeria. Afr J Microbiol Res. 2015;9:355-9.
6
Nicolle LE. Management of asymptomatic bacteriuria in pregnant women. Lancet Infect Dis. 2015;15:1252-4.
7
Raj RS, Bonney EA, Phillippe M. Influenza, Immune System, and Pregnancy. Reprod Sci. 2014;21:1434-51.
8
Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL, Biggerstaff MS, Lindstrom S, Louie JK, Christ CM, Bohm SR, Fonseca VP, Ritger KA, Kuhles DJ, Eggers P, Bruce H, Davidson HA, Lutterloh E, Harris ML, Burke C, Cocoros N, Finelli L, MacFarlane KF, Shu B, Olsen SJ; Novel Influenza A (H1N1) Pregnancy Working Group. H1N1 2009 Influenza Virus Infection During Pregnancy in The USA. Lancet. 2009;374:451-8.
9
Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, Fifteenth Informational (Suppl) Volume 25 M100-S15. Wayne, PA: CLSI:2005;98-101.
10
Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennet JE, Dolin R (eds). Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingstone, 2010:957-85.
11
Thielman NM, Guerrant RL. Clinical practice. Acute infectious diarrhea. N Engl J Med. 2004;350:38-47.
12
Delzell JE Jr, Lefevre ML. Urinary tract infections during pregnancy. Am Fam Physician. 2000;61:713-21.
13
Wing DA, Fassett MJ, Getahun D. Acute pyelonephritis in pregnancy: an 18-year retrospective analysis. Am J Obstet Gynecol. 2014;210:219.
14
Thurman AR, Steed LL, Hulsey T, Soper DE. Bacteriuria in pregnant women with sickle cell trait. Am J Obstet Gynecol. 2006;194:1366-70.
15
Romero R, Oyarzun E, Mazor M, Sirtori M, Hobbins JC, Bracken M. Metaanalysis of the relationship between asymptomatic bacteriuria and preterm delivery/low birth weight. Obstet Gynecol. 1989;73:576-82.
16
Kazemier BM, Koningstein FN, Schneeberger C, Ott A, Bossuyt PM, de Miranda E, Vogelvang TE, Verhoeven CJ, Langenveld J, Woiski M, Oudijk MA, van der Ven JE, Vlegels MT, Kuiper PN, Feiertag N, Pajkrt E, de Groot CJ, Mol BW, Geerlings SE. Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy: a prospective cohort study with an embedded randomised controlled trial. Lancet Infect Dis 2015;15:1324-33.
17
Stenqvist K, Sandberg T, Lidin-Janson G, Orskov F, Orskov I, Svanborg-Edén C. Virulence factors of Escherichia coli in urinary isolates from pregnant women. J Infect Dis. 1987;156:870-7.
18
Hill JB, Sheffield JS, McIntire DD, Wendel GD Jr. Acute pyelonephritis in pregnancy. Obstet Gynecol 2005;105:18-23.
19
Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009;34:407-13.
20
Ho PL, Yip KS, Chow KH, Lo JY, Que TL, Yuen KY. Antimicrobial resistance among uropathogens that cause acute uncomplicated cystitis in women in Hong Kong: a prospective multicenter study in 2006 to 2008. Diagn Microbiol Infect Dis. 2010;66:87-93.
21
Pathak A, Chandran SP, Mahadik K, Macaden R, Lundborg CS. Frequency and factors associated with carriage of multidrug resistant commensal Escherichia coli among women attending antenatal clinics in central India. BMC Infect Dis. 2013;13:199.
22
Gozel MG, Elaldi N, Engin A, Akkar OB, Bolat F, Celik C. Favorable outcomes for both mother and baby are possible in pregnant women with crimeancongo hemorrhagic fever disease: A case series and literature review. Gynecol Obstet Invest. 2014;77:266-71.
23
Pshenichnaya NY, Leblebicioglu H, Bozkurt I, Sannikova IV, Abuova GN, Zhuravlev AS, Barut S, Shermetova MB, Fletcher TE. Crimean-Congo hemorrhagic fever in pregnancy: A systematic review and case series from Russia, Kazakhstan and Turkey. Int J Infect Dis. 2017;58:58-64.
24
Ascioglu S, Leblebicioglu H, Vahaboglu H, Chan KA. Ribavirin for patients with Crimean-Congo haemorrhagic fever: A systematic review and metaanalysis. J Antimicrob Chemother. 2011;66:1215-22.
25
O"Toole D, Williams ES, Woods LW, Mills K, Boerger-Fields A, Montgomery DL, Jaeger P, Edwards WH, Christensen D, Marlatt W. Tularemia in range sheep: an overlooked syndrome? J Vet Diagn Invest. 2008;20:508-13.
26
Yeşilyurt M, Kiliç S, Çelebі B, Gül S. Tularemia during pregnancy: report of four cases. Scand J Infect Dis. 2013;45:324-8.
27
Dentan C, Pavese P, Pelloux I, Boisset S, Brion JP, Stahl JP, Maurin M. Treatment of tularemia in pregnant woman, France. Emerg Infect Dis. 2013;19:996-8.
28
Yilmaz GR, Guven T, Guner R, Kilic S, Gulen TA, Eser FC, Tasyaran MA. Tularemia during pregnancy: three cases. Vector Borne Zoonotic Dis. 2014;14:171-3.
29
Ata N, Kılıç S, Övet G, Alataş N, Çelebi B. Tularemia during pregnancy. Infection. 2013;41:753-6.
30
Celik T, Kosker M, Kirboga K. An atypical case of tularemia presented with pseudoptosis. Infection. 2014;42:785-8.
31
Carlson A, Thung SF, Norwitz ER. H1N1 Influenza in Pregnancy: What All Obstetric Care Providers Ought to Know. Rev Obstet Gynecol. 2009;2:139-45.
32
Centers for Disease Control and Prevention (CDC). Novel İnfluenza A (H1N1) Virus Infections in Three Pregnant Women - United States, April-May 2009. MMW Morb Mortal Wkly Rep. 2009;58:497-500.